Amy J Johnson
Amy J Johnson
Vincerx Pharma
Verified email at
Cited by
Cited by
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ...
New England Journal of Medicine 369 (1), 32-42, 2013
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ...
New England Journal of Medicine 370 (24), 2286-2294, 2014
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ...
New England Journal of Medicine 374 (4), 323-332, 2016
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ...
Blood 117 (23), 6287-6296, 2011
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ...
Blood 117 (2), 591-594, 2011
Three-year follow-up of treatment-na´ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ...
Blood, blood-2014-10-606038, 2015
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ...
Blood 122 (15), 2539-2549, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ...
The lancet oncology 15 (1), 48-58, 2014
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survivalá…
SEM Herman, AL Gordon, AJ Wagner, NA Heerema, W Zhao, JM Flynn, ...
Blood 116 (12), 2078-2088, 2010
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
AG Ramsay, AJ Johnson, AM Lee, G GorgŘn, R Le Dieu, W Blum, JC Byrd, ...
The Journal of clinical investigation 118 (7), 2427-2437, 2008
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
KJ Maddocks, AS Ruppert, G Lozanski, NA Heerema, W Zhao, L Abruzzo, ...
JAMA Oncology 1 (1), 80-87, 2015
Genetic heterogeneity of diffuse large B-cell lymphoma
J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ...
Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013
The B-cell receptor signaling pathway as a therapeutic target in CLL
JA Woyach, AJ Johnson, JC Byrd
Blood 120 (6), 1175-1184, 2012
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ...
Blood 127 (9), 1117-1127, 2016
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437-1443, 2017
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ...
Blood 109 (2), 399-404, 2006
Single-agent ibrutinib in treatment-na´ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
S O’Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, ...
Blood 131 (17), 1910-1919, 2018
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
R Lapalombella, Q Sun, K Williams, L Tangeman, S Jha, Y Zhong, ...
Blood 120 (23), 4621-4634, 2012
Ibrutinib treatment improves T cell number and function in CLL patients
M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ...
The Journal of Clinical Investigation 127 (8), 3052-3064, 2017
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
JA Woyach, K Smucker, LL Smith, A Lozanski, Y Zhong, AS Ruppert, ...
Blood 123 (12), 1810-1817, 2014
The system can't perform the operation now. Try again later.
Articles 1–20